The p53 tumor suppressor gene encodes a transcription factor that is commonly mutated in cancer. Tumors arise when premalignant cells are unable to undergo p53-dependent apoptosis, cell cycle arrest or DNA repair. The p53-signaling pathway affects not only tumor development, but also the response of tumors to chemotherapeutic drugs. In this study, we use cell penetrating peptide conjugates of phosphorodiamidate morpholino oligomers (PPMOs) to inhibit p53 expression. We examine the functional properties of endogenous p53 isoforms that are produced upon PPMO-mediated inhibition of p53 translation and splicing, and report that loss of N-terminal or C-terminal sequences interferes with the transcriptional activity of p53. Importantly, we report that PPMOmediated inhibition of p53 expression sensitizes human cancer cells with wild-type p53 to chemotherapeutic drugs.
Introduction
Phosphorodiamidate morpholino oligomers (PMOs) are a novel class of single-stranded antisense oligomers in which the ribose sugar is replaced with a six-membered morpholine ring and the phosphorodiester linkage is replaced with a phosphorodiamidate linkage. PMOs contain a neutral backbone that lessens non-specific interactions, increases resistance to enzyme degradation and enhances affinity for target RNA sequences compared with some oligonucleotides with a charged backbone (Iversen, 2001) . Unlike conventional antisense oligonucleotide-based strategies that inhibit gene expression by triggering RNase H-mediated cleavage of RNA:DNA duplexes, PMOs do not elicit RNase H activity. PMOs bind to target RNA sequences and sterically block ribosomal assembly interfering with translation initiation, or block intron-exon splice junctions interfering with pre-mRNA splicing.
A recent and important development to improve delivery of PMOs into cells in culture involves conjugation to basic amino acid-rich peptides (Nelson et al., 2005) . PMOs conjugated to cell penetrating peptides (PPMOs) do not require transfection reagent, membrane permeabilization or scrape loading to enter target cells. PPMOs have been reported to inhibit the expression of endogenous genes, as well as the replication of pathogenic human viruses in cell culture and in mouse models (Abes et al., 2008) . In this study, various arginine-rich PPMOs were designed to target the translational start codon in p53 mRNA and splicing sites in p53 pre-mRNA. These were screened and evaluated for their effectiveness at repressing p53 expression and function.
The p53 gene is commonly mutated in human cancer, losing its ability to induce apoptosis and to promote growth arrest/cellular senescence. In tumors, where the p53 gene remains wild type, p53 protein levels are often kept low through the action of negative regulatory proteins like Mdm2, an E3 ubiquitin ligase that promotes the proteolytic degradation of p53. As a result, p53-based tumor therapies under development are primarily directed in three areas: activating mutant p53 in tumors by forcing it in a wild-type conformation; increasing the levels of wild-type p53 expression in tumor cells by inhibiting its interaction with molecules such as Mdm2; and restoring p53 function in established tumors. The p53, however, can also promote the survival of damaged cells through a large number of mechanisms including control of the G1 checkpoint, DNA repair and anti-oxidant defences (Kim et al., 2009; Vousden and Prives, 2009 ). The dual function of p53 in promoting death or survival raises many important questions regarding the cellular responses to p53 activation. The dual function of p53 must also be considered in the treatment of tumors that retain wild-type p53 alleles. Thus, in certain clinical settings where the predominant tumor response to druginduced p53 activation is survival rather than death, the repression of p53 may increase sensitivity to chemotherapeutic drugs (Bunz et al., 1999; McGill and Fisher, 1999) . The identification of PPMOs that effectively inhibit p53 expression in human tumor cells allowed us to test the effect of p53 repression on drug sensitivity.
Results
PPMOs block p53 expression and generate p53 isoforms To investigate the effectiveness of PMOs in blocking p53 expression, we treated wild-type p53 expressing MCF7 breast cancer cells with PMOs and PPMOs targeting the translation initiation site of p53 mRNA (M1), the splice acceptor site of exon 10 (E10SA) and the coding region within exon 10 (E10; Supplementary Table 1) . The cell penetrating peptide (CPP) used was (RX) 8 B where R ¼ arginine, X ¼ 6-aminohexanoic acid and B ¼ b-alanine. No overt indications of cellular toxicity were observed over the duration of the experiments at the concentrations of oligos tested. CPP-E10SA interfered with the expression of p53 and produced a smaller stable polypeptide of approximately 48 kDa (p48); an even smaller polypeptide was observed at higher doses of CPP-E10SA (Figure 1 ). CPP-M1 interfered with p53 expression and produced a stable polypeptide of approximately 44 kDa (p44). The corresponding PMOs without conjugation to the CPP had no effect. E10 targets neither translation initiation nor splicing sites and had no effect on p53 expression regardless of peptide conjugation.
To characterize the smaller, p53-related polypeptides further, we immunoblotted with antibodies directed to specific epitopes of p53: D01 (aa 11-21), PAb1801 (aa 46-55) and PAb421 (aa 372-382). D01 recognized full-length p53 and p48, but not p44; PAb1801 recognized full-length p53, p48 and p44; and PAb421 recognized full-length p53, albeit very weakly, and p44 strongly, but not p48 (Figure 1 ). These epitope mapping results indicate that p44 and p48 are the missing sequences at the N-terminus and at the C-terminus of the molecule, respectively (Supplementary Figure 1) . Moreover, they indicate that p44 and p48 are very stable relative to full-length p53 protein.
The p44 likely corresponds to DN-p53 (also referred to as p47 or p53/p47), a previously identified stable isoform of p53 that is produced by internal initiation of translation at codon 40 in human p53 mRNA (Courtois et al., 2002; Yin et al., 2002; Ghosh et al., 2004; Bourdon et al., 2005; Ray et al., 2006) and at codon 41 in mouse p53 mRNA. Mouse p44 was initially detected in an erythroleukemia cell line with a deletion of p53 exon 2 that removed the normal translation initiation site (Rovinski et al., 1987) . DN-p53 lacks the N-terminal Mdm2 binding site and as a result, will not undergo Mdm2-mediated ubiquitination and degradation.
The p48 likely corresponds to p53b (also named p53i9) or p53g, two C-terminally truncated p53 variants produced by alternative splicing of exon 9 to one of two sites in intron 9 (Flaman et al., 1996; Bourdon et al., 2005) . Both p53b and p53g terminate at Gln331 of p53 and lack amino acids 332-393, which include the oligomerization domain of p53; p53b has 10 additional amino acids and p53g has 15 additional amino acids derived from intron 9 sequences. We were unable to distinguish between these two p53 variants. The elevated level of p53b/g in unstressed cells is consistent with previous reports identifying six C-terminal lysines of p53 (K370, K372, K373, K381, K382, K386) as targets for Mdm2-mediated ubiquitination (Nakamura et al., 2000; Rodriguez et al., 2000; Lohrum et al., 2001 ). These results demonstrate that two distinct endogenous p53 protein isoforms can be expressed in MCF7 cells when PPMOs are used to interfere with translation initiation at codon 1 or with splicing at the splice acceptor site of exon 10.
PPMOs block p53 expression and p21 induction after DNA damage To investigate the expression and function of p44 (DNp53) and p48 (p53b/g) isoforms in a broader range of cells under stress conditions that activate p53, we treated H460 lung cancer cells with doxorubicin, HCT116 colon cancer cells with 5-fluorouracil (5-FU), and OCI/AML-3 and OCI/AML-4 leukemia cells with g-radiation. All of these human cancer cell lines express wild-type p53 and respond to DNA damage by increasing p53 protein levels and activating expression of the p53-target gene, p21 (Figure 2 ). Pre-treatment for 2 h with CPPconjugated M1 or E10SA (all oligos used from this point forward are PPMOs containing the CPP and will be identified by the oligo name only) before DNA damage led to the production of DN-p53 and p53b/g, respectively, as seen previously in MCF7 cells. The levels of these stable p53 isoforms did not increase appreciably after DNA damage. Both M1 and E10SA interfered with the accumulation of full-length p53 and with the induction of p21 after DNA damage. CPP-conjugated Figure 1 PPMOs interfere with p53 expression in non-stressed MCF7 cells and give rise to p53 isoforms. Western blot analysis of p53 expression in MCF7 cells. MCF7 cells were treated with increasing concentrations (0, 1, 3, 10 mM) of CPP-conjugated PMOs or with non-conjugated PMOs for 2 h. Cells were incubated in fresh medium for an additional 24 h before analysis, using four antibodies against p53. The CPP-PMOs consisted of (RX) 8 B conjugated to the 5 0 end of the PMOs. A non-specific cross-reactive protein detected with the FL393 antibody serves as a protein loading control.
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Evaluation of different CPPs
To evaluate whether different arginine-rich peptides might improve the efficiency of the M1 PMO to block translation of p53 mRNA from codon 1, we conjugated two different arginine-rich peptides to the 3 0 end of M1, (RXR) 4 XB and (RXRRBR) 2 XB, and compared these with the original CPP-M1 containing the (RX) 8 B sequence at the 5 0 end. There was little, if any, detectable difference in the efficiency of the three arginine-rich peptides to repress translation from the targeted codon 1 of the p53 transcript (Supplementary Figure 2) .
Evaluation of PPMOs that target p53 mRNA splicing
We tested a panel of PPMOs that target splice sites in exons 2, 4, 6, 7 and 9 of the human p53 gene (Supplementary Table 1 ). With the exception of E2SD that targets the splice donor site of exon 2, the remaining PPMOs exhibited variable effectiveness in suppressing p53 protein expression in H460 cells, revealed no new isoforms and did not block expression of p21 in response to doxorubicin (Supplementary Figure 3) . E2SD produced a 44-kDa isoform that resembled DN-p53 in terms of its mobility following gel electrophoresis and antibody binding (PAb1801-positive, PAb421-positive and DO1-negative); moreover, the E2SD product prevented the induction of p21 in response to doxorubicin treatment (Supplementary Figure 4) . These results are consistent with those of Ghosh et al. (2004) who reported that DN-p53 can arise through a naturally occurring, but less abundant, alternatively spliced p53 transcript in which intron 2 sequences are not removed. The alternatively spliced transcript contains an intron 2-derived in-frame termination codon that arrests translation prematurely and was predicted to produce DN-p53 from codon 40. Our findings suggest that E2SD and M1 produce identical truncated DN-p53 proteins through two different mechanisms: alternative splicing of exon 2 and alternative initiation of translation at codon 40.
CP-PMO-mediated repression of p53 disrupts p53-dependent cell cycle arrest in G1 and p53-dependent apoptosis Next, we determined if PPMO-mediated repression of p53 disrupts its ability to promote apoptosis in response to DNA damage. We treated HCT116 p53 þ / þ and HCT116 p53
À/À cells with 5-FU (50 mg/ml) for 48 h and subjected the cells to flow cytometry. A proportion of the p53 þ / þ cells, but not the p53 À/À cells, had a sub-G1 DNA content characteristic of apoptotic cells (Figure 3a ), confirming that HCT116 cells undergo p53-dependent apoptosis in response to 5-FU (Bunz et al., and OCI/AML4 cells 5 h after g-irradiation (5 Gy). Cells were pre-treated with the indicated PPMOs (3 mM) for 2 h before irradiation or drug treatment. The PPMOs consisted of (RX) 8 B conjugated to the 5 0 end of the PMOs. The p53 was detected with PAb1801. A non-specific cross-reactive protein detected with the p21 antibody serves as a protein loading control.
p53 inhibition enhances drug sensitivity W Ma et al 1999). Pre-treatment of HCT116 p53 þ / þ cells with M1 or E10SA, but not E10, blocked apoptosis by 5-FU (Figure 3a) . These results indicate that DN-p53 (produced in response to M1) and p53b/g (produced in response to E10SA) are defective in promoting apoptosis.
In contrast to HCT116 cells treated with 5-FU, H460 cells treated with doxorubicin (200 ng/ml) for 48 h undergo predominantly cell cycle arrest in G1 and G2/ M and not cell death (Figure 3b ). In the absence of doxorubicin, M1 and E10SA had no effect on the cell cycle profile of H460 cells. In the presence of doxorubicin, however, both M1 and E10SA reduced the proportion of cells undergoing G1 arrest, with no detectable effect on G2/M arrest (Figure 3b ). This indicates that H460 cells undergo p53-dependent G1 arrest, and that, DN-p53 and p53b/g are defective at promoting G1-cell cycle arrest. Together, these data indicate that M1 and E10SA independently suppress p53-dependent cellular responses to DNA damage.
Complete inhibition of p53 expression with PPMOs that target the translational start codon (Met1) and Met40 As the inhibition of stress-induced p53 expression has potential clinical use in various pathologies including cancer (Gudkov and Komarova, 2003; Bertheau et al., 2008) , we wanted to identify PPMOs that completely block p53 expression. Although M1 and E2SD prevent expression of full-length p53 and allow the expression of DN-p53 protein that lacks transcriptional activity at the p21 promoter, we were concerned that the N-terminally truncated p53 protein might retain transcriptional activity on other promoters, or that it might possess novel and unanticipated functions (Harms and Chen, 2006) . Moreover, DN-p53 retains the oligomerization domain of p53 and might, therefore, function as a transdominant repressor of p53 family members including p63 or p73 (Maier et al., 2004) , raising substantive concerns with any intervention strategy that produces DN-p53. E10SA also prevents expression of full-length p53, but gives rise to p53b/g. Although p53b/g lacks the oligomerization domain and was reported to lack transcriptional activity, it retains the ability to bind certain p53-response elements on DNA (Bourdon et al., 2005) and to cooperate with full-length p53 (Fujita et al., 2009) .
To address these concerns, we designed a PPMObased strategy to block translation from codon 1 and codon 40 (within exon 4). When the methionine codons at positions 1 are 40 are bypassed, the next available methionine codon bearing a Kozak consensus sequence p53 inhibition enhances drug sensitivity W Ma et al for translation initiation occurs in codon 160 (within exon 5). A p53 mRNA variant that initiates in intron 4 from an internal promoter was previously identified and predicted to initiate translation at codon 133 giving rise to D133p53 (Bourdon et al., 2005) . An N-terminal truncated p53 protein likely initiating from codon 133 was also reported to be expressed in a human choriocarcinoma cell line with a deletion of p53 exons 2, 3 and 4 (Horikawa et al., 1995) . When used alone, M40 (targeting codon 40 of p53 mRNA) repressed expression of full-length p53 in a dose-dependent manner, presumably through steric hindrance of the translation elongation machinery, and produced a novel polypeptide of about 35 kDa that was recognized by DO1 and FL393, but not PAb1801 (Figures 4a and b) . This could reflect translation of a splicing variant that contains exon 2 sequences (DO1 epitope) and is missing exon 4 sequences (PAb1801 epitope). Expression of p21 was suppressed but not eliminated by M40, even when used at a high concentration (10 mM). When M40 was used together with M1, however, we observed complete suppression of p53 and DN-p53 (Figure 4b ). This result confirms that DN-p53 initiates from codon 40. A smaller polypeptide of about 33 kDa was detected very weakly by FL393 (and not by PAb1801 or DO1) in H460 cells treated with M1 and M40. This could represent a p53 translation product initiating from codon 133 (D133p53) or codon 160. The western blot presented in Figure 4b confirms that M1 prevents induction of p21 after DNA damage and additionally shows that M1 prevents induction of another p53 target gene, Mdm2. Similar results were obtained with two different, but related, PPMOs, M1-A and M40-B (Supplementary Table 1 and Supplementary Figure 5a) . We propose that the combined use of M1 and M40 (or M1-A and M40-B) provides an effective strategy to block both full-length p53 and DN-p53 protein expression and p53 transcriptional activity in human cells.
PPMO-mediated repression of p53 sensitizes H460 and U2OS cells to doxorubicin-and cisplatin-induced apoptosis
To investigate the role of p53 in determining the sensitivity of H460 cells to doxorubicin, we used PPMOs to repress p53 expression. H460 cells were pre-treated with M1 alone, M40 alone or both M1 and M40, before treatment with doxorubicin (200 ng/ml) for 72 h. Apoptosis was measured using propidium iodide staining and flow cytometry to identify cells with sub-G1 DNA content (Figures 5a and b) and by a highly sensitive fluorescent assay that measures caspase-3 activation (Figure 5c ). In the previous experiments reported in Figure 3b , we treated H460 cells with doxorubicin for 48 h and observed predominantly cell cycle arrest. After longer treatment (72 h), a small proportion of apoptotic cells could be detected ( Figure 5 ). Both apoptotic assays indicated a significant enhancement of doxorubicininduced apoptosis when M1 was used to block p53 expression. The combined use of M1 and M40 was not more effective than M1 alone in sensitizing H460 cells to doxorubicin-induced cell death. PPMO-mediated p53 repression also enhanced the sensitivity of H460 cells to (Figure 5d and Supplementary Figure 4b ). To examine the role of p53 in determining chemosensitivity in another tumor cell line, we chose the wild-type p53 expressing U2OS human osteosarcoma. Inhibition of p53 enhanced the sensitivity of U2OS cells to doxorubicin-and cisplatin-induced apoptosis ( Figure 6 ). These results unmask a prosurvival function of full-length wild-type p53 in cancer cells that limits the effectiveness of doxorubicin and cisplatin in killing these cells.
The combined use of M1 and M40 blocks mutant p53 expression in MDA-MB-468 breast carcinoma cells Unlike mutations in other tumor suppressor genes, most p53 mutations in human cancer are missense mutations that lead to the synthesis of stable p53 protein that has lost its normal functions. The retention of mutant p53 in human tumors rather than complete loss of p53 could reflect a gain-of-function for mutant p53. The generation of mutant p53 knock-in mice that display aggressive and metastatic tumors not seen in p53-null mice provides strong support for this idea (Lang et al., 2004; Olive et al., 2004) . Additional support has been provided by a computational study of p53 mutation hotspots in clinical samples (Koonin et al., 2005) . Moreover, mutant p53 expression has been associated with increased cell proliferation, migration, invasion and metastasis through suppression of the p53 family member p63 (Adorno et al., 2009; Muller et al., 2009) . Mutant p53 has also been shown to promote tumor cell survival (Lim et al., 2009; Stambolsky et al., 2010) . These findings suggest that targeting mutant p53 in highly aggressive human tumors could provide therapeutic benefit. To test the ability of M1 and M40 to inhibit mutant p53 expression, we treated the breast carcinoma cell line MDA-MB-468 that expresses mutant (R273H) p53. M1 treatment inhibited full-length p53 expression and produced DN-p53. When used together, M1 and M40 reduced full-length p53 without producing DN-p53. A control PPMO had no effect on p53 expression (Figure 7a ). These data indicate that M1 and M40 are effective in blocking mutant p53 expression in human p53 inhibition enhances drug sensitivity W Ma et al tumor cells. In contrast to H460 and U2OS cells, inhibition of R273H p53 expression in MDA-MB-468 cells did not enhance the apoptotic response of these cells to doxorubicin (Figure 7b ). It will be important to evaluate the consequences of PPMO-mediated p53 repression in other tumor cell lines expressing different mutant p53 alleles, and in xenograft models where mutant p53 has been reported to regulate cell migration, invasion and metastasic behavior.
Discussion
The role of p53 in determining the cellular response to chemotherapeutic drug treatment is complex and is dependent on cell type, p53 mutational status and the drug used. In some experimental models, p53-deficiency is associated with resistance to DNA damaging agents, whereas in other models, p53-deficiency leads to enhanced drug sensitivity (Lowe et al., 1993a, b; O'Connor et al., 1997; Bunz et al., 1999; McGill and Fisher, 1999; El-Deiry, 2003) . One view is that p53 is required to promote apoptosis in response to DNA damage; in the absence of p53, cells survive DNA damage because of their inability to undergo apoptosis. The contrasting view is that cells with an intact p53-dependent checkpoint and/or p53-dependent survival functions are resistant to DNA damage (Fei et al., 2002; Gudkov and Komarova, 2003) . In this study, we use PPMOs to inhibit wild-type p53 expression and report that p53 inhibition sensitizes H460 lung cancer cells and U2OS osteosarcoma cells to doxorubicin and cisplatin. Our studies suggest that p53 has a pro-survival function that limits the effectiveness of doxorubicin and cisplatin in killing tumor cells. In contrast, the same PPMOs block p53-dependent apoptosis in HCT116 cells treated with 5-FU. Hence, in certain tumor cells where the predominant response to p53 activation is not apoptosis, but rather G1 cell cycle arrest and/or survival, the inhibition of p53's protective function may render these cells sensitive to drugs that promote cell death through p53-independent processes.
It remains unclear how p53 determines strikingly different cellular responses to DNA damage, how the protective and sensitizing roles for p53 are controlled and how p53 expression or p53 gene status (wild type or mutant) affects drug sensitivity in a clinical setting. Transient p53-dependent cell cycle arrest in response to DNA damage could provide cells with time to repair the damage before DNA synthesis or cell division. In addition, p53 can regulate the expression of antioxidant genes, metabolic genes and DNA repair genes that may influence drug sensitivity and cell survival (Vousden and Prives, 2009) . Our results support the view that p53's pro-survival function could mitigate the effects of chemotherapy on tumor cells with wild-type p53 (Kim et al., 2009) . A broader study is required to identify the tumor-drug combinations that best respond to p53 repression. In light of the accumulating evidence showing that p53 mutations may confer dominantnegative or gain-of-function properties to p53 and that mutant p53 alleles exhibit enhanced oncogenic potential beyond the simple loss of p53 function, a PMO-based strategy to inhibit mutant p53 expression in a clinical setting should also be considered.
Transient p53 repression may be beneficial not only in tumor cells, but also as a means of limiting normal tissue damage in response to radiotherapy and chemotherapy. Reducing p53 induction may also be therapeutically beneficial in a wide variety of medical disorders that involve p53-dependent programmed cell death, such as during ischemia or during subsequent reperfusion injury and in various neurodegenerative diseases.
Our study also addresses the expression and function of various p53 isoforms generated through alternative initiation of translation, usage of an internal promoter and alternative splicing. The N-terminus of p53 is reported to contain two independent transcription activation (TA) domains, TA1 (residues 1-40) and TA2 (residues 43-63). DN-p53 is missing TA1, but retains TA2. Previous studies (Zhu et al., 1998; Yin et al., 2002) reported that ectopic expression of DN-p53 activates a subset of p53 target genes including Mdm2 and Bax through TA2; moreover, DNp53 retains the ability to induce apoptosis. In contrast, our results show that endogenously expressed DN-p53 lacks the ability to activate p21 and Mdm2 expression in stressed or unstressed cells and lacks the ability to promote apoptosis in response to DNA damage.
Materials and methods

Cell culture
The human colon carcinoma cell lines HCT116 and HCT116 p53 À/À were kindly provided by Dr B Vogelstein (Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) and were cultured in McCoy's 5A medium; H460 (human lung cancer) cells were cultured in RPMI 1640 medium; U2OS (human osteosarcoma) cells were cultured in McCoy's 5A medium; MDA-MB-468 (human breast cancer) cells were cultured in Dulbecco's modified Eagle medium (high glucose) medium; MCF7 (human breast cancer) cells were cultured in a-minimum essential medium; OCI/AML3 and OCI/AML4 (human leukemia) cells were obtained from Dr M Minden (Ontario Cancer Institute, Toronto, Ontario, Canada) and were cultured in aminimum essential medium. All media were supplemented with 10% fetal bovine serum (Hyclone Laboratories Inc., South Logan, UT, USA) and antibiotics. The medium for OCI/AML4 cells was supplemented with 10% conditioned medium from the bladder carcinoma cell line 5637 (Wang et al., 1989) . All cells were cultured at 37 1C in a 5% CO 2 incubator.
PMO design and treatment
PMOs were synthesized by methods previously described (Summerton and Weller, 1997) . The CPPs (RXR) 4 XB and (RXRRBR) 2 XB (where R ¼ arginine, X ¼ 6-aminohexanoic acid and B ¼ b-alanine) were covalently conjugated to the 3 0 end of each PMO, and (RX) 8 B was covalently conjugated to the 5 0 end of each PMO through a noncleavable piperazine linker by methods previously described (Wu et al., 2007) . Lyophilized PMOs and PPMOs were dissolved in sterile water to a concentration of 2 mM and stored in the dark at 4 1C. The PMOs and PPMOs were diluted to 0.2 mM in sterile water immediately before use. Cells were seeded in 10-cm dishes and treated with PMOs or PPMOs for 2 h in 3 ml of growth medium lacking antibiotics and fetal bovine serum. At the end of this period, the medium was removed, the cells were washed with growth medium, and the cells were placed in fresh growth medium containing antibiotics and fetal bovine serum. The cells were then exposed to drug or g-irradiated as described in the text.
Flow cytometry for cell cycle analysis and apoptosis Cells were fixed on ice in cold 70% ethanol, washed twice with phosphate-buffered saline containing 1% bovine serum albumin, incubated with 100 mg/ml RNase A for 30 min at 37 1C, and resuspended in phosphate-buffered saline containing 50 mg/ml propidium iodide. Cell cycle distribution was examined by flow cytometry using a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed using ModFit LT 3.2. Apoptosis was assessed by flow cytometry using sub-G1 DNA content and by caspase activity using a cell membrane-permeable fluorogenic caspase-3 substrate in non-fixed cells as described by the manufacturer (Biotium, Inc., Hayward, CA, USA; product #30 029).
Western blot analysis Cells were lysed in 1% NP40, 50 mM Tris (pH 8.0), 5 mM ethylene diamine tetraacetic acid and 150 mM NaCl supplemented with protease inhibitors. Total protein (40 mg) was separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. The following antibodies to p53 were used: DO-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), FL393 (Santa Cruz), PAb1801 (Banks et al., 1986) and PAb421 (Harlow et al., 1981) . Antibodies to p21 and Mdm2 were obtained from Santa Cruz and to b-actin from Sigma-Aldrich p53 inhibition enhances drug sensitivity W Ma et al Canada Ltd. (Toronto, ON, Canada). Anti-rabbit and antimouse secondary antibodies were conjugated with horseradish peroxidase and blots were visualized using enhanced chemiluminescence (Perkin Elmer Canada, Woodbridge, ON, Canada).
Statistical analyses
The proportion of cells undergoing apoptosis is presented as the mean; error bars represent the s.e.m. The unpaired Student's t-test was used to determine the statistical significance of differences between means.
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